The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...

The FDA has approved Kisqali (ribociclib) in adults with HR-positive, HER2-negative stage II and III early breast cancer.

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...